RJS Biologics is pioneering a unique drug delivery platform aimed at enhancing the efficacy of cancer treatments while minimizing adverse effects. Their pipeline includes several therapeutic candidates, such as EGFR inhibitors (RJS012 and RJS013) designed to selectively target lung cancer cells. These compounds aim to reduce the skin reactions commonly associated with current epidermal growth factor inhibitor therapies, potentially allowing for more consistent treatment regimens. Additionally, the company is developing anthracycline-based therapies (RJS010) that focus on leukemia and lymphoma cells, addressing the severe side effects linked to traditional Doxorubicin treatments, which can lead to significant heart damage in patients.

Another innovative aspect of RJS Biologics' approach is the use of Artemisinin (RJS05X), which, when combined with their targeted delivery system, shows promise in effectively combating leukemia and lymphoma by exploiting the high iron intake of these cancer cells. Furthermore, RJS Biologics is working on companion imaging agents through their tethering technology, which allows for real-time imaging of their drug candidates in action against cancer. This multifaceted approach not only aims to improve therapeutic outcomes but also enhances diagnostic capabilities, providing a comprehensive strategy for cancer treatment and monitoring.

United States

Cancer Drug Delivery Technology - enhances drug delivery with small molecule affinity-tethering compounds

RJS Biologics

Company Details